Ligand Pharmaceuticals Inc. (LGND) — 分析摘要
Ligand Pharmaceuticals Inc.(LGND)的市值为6.20十亿美元,最近一年的营收同比增长了+60.4%。净利润率为46.4%。当前市盈率为40.4倍。
核心要点
- 营收同比变化+60.4%
- 净利润率46.4%
- 市盈率40.4倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,LGND的营收增长为+60.4%,市盈率为40.4倍。
Ligand Pharmaceuticals Inc. (LGND)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号,应与估值结果一并解读。
营业利润率 (34.5%) 超过毛利率 (0.0%) — 请检查其他营业收入或数据分类问题
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
47
总部
SAN DIEGO, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
N/A
股息收益率
N/A
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。